PTC Therapeutics Inc [PTCT] stock prices are down -0.65% to $33.77 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The PTCT shares have gain 7.48% over the last week, with a monthly amount glided 2.21%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
PTC Therapeutics Inc [NASDAQ: PTCT] stock has seen the most recent analyst activity on September 04, 2024, when Robert W. Baird initiated its Outperform rating and assigned the stock a price target of $44. On May 20, 2024, upgrade upgraded it’s rating to Mkt Perform. Morgan Stanley downgraded its rating to a Underweight but stick to its price target of $28 on December 19, 2023. Wells Fargo initiated its recommendation with a Overweight and recommended $37 as its price target on December 08, 2023. Oppenheimer upgraded its rating to Outperform for this stock on October 30, 2023, but kept the price target unchanged to $165. In a note dated October 27, 2023, Citigroup downgraded an Sell rating on this stock and revised its target price from $29 to $17.
The stock price of PTC Therapeutics Inc [PTCT] has been fluctuating between $17.53 and $40.69 over the past year. Currently, Wall Street analysts expect the stock to reach $44.33 within the next 12 months. PTC Therapeutics Inc [NASDAQ: PTCT] shares were valued at $33.77 at the most recent close of the market. An investor can expect a potential return of 31.27% based on the average PTCT price forecast.
Analyzing the PTCT fundamentals
The PTC Therapeutics Inc [NASDAQ:PTCT] reported sales of 900.45M for trailing twelve months, representing a drop of -12.68%. Gross Profit Margin for this corporation currently stands at 0.78% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.55%, and Net Profit Margin reading is -0.53%. To continue investigating profitability, this company’s Return on Assets is posted at -0.25, Equity is 0.57 and Total Capital is -0.15. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-0.31.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 33.49 points at the first support level, and at 33.21 for the second support level. However, for the 1st resistance point, the stock is sitting at 34.14, and for the 2nd resistance point, it is at 34.50.
Ratios To Look Out For
It’s worth pointing out that PTC Therapeutics Inc [NASDAQ:PTCT]’s Current Ratio is 2.23. As well, the Quick Ratio is 2.17, while the Cash Ratio is 1.07. Considering the valuation of this stock, the price to sales ratio is 2.88.
Transactions by insiders
Recent insider trading involved Gravier Pierre, CHIEF FINANCIAL OFFICER, that happened on Jul 16 ’24 when 2269.0 shares were sold. Director, ZELDIS JEROME B completed a deal on May 22 ’24 to sell 20000.0 shares. Meanwhile, EVP & CHIEF MEDICAL OFFICER Golden Lee Scott sold 175.0 shares on May 07 ’24.
